The Tina Trial: A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine “Ice” dependence

May 2021

Associate Professor Rebecca McKetin

Scientia Professor Louisa Degenhardt

Professor Michael Farrell

Ms Samantha Colledge

Other investigators: 

Professor Gregory Dore, Kirby Institute UNSW

Professor Steven Shoptaw, University of California Los Angeles (UCLA)

Associate Professor Peter Kelly, University of Wollongong

Dr Alyna Turner, Deakin University

Dr Philip Clare, University of Sydney

Dr Shalini Arunogiri, Monash University

Professor Michael Berk, Deakin University

Associate Professor Olivia Dean, Deakin University

Dr Barbara Sinclair, Illawarra Shoalhaven Local Health District

David Reid, Illawarra Shoalhaven Local Health District

Dr Jeremy Hayllar, Metro North Hospital and Health Service

Dr David Goodman, University of California Los Angeles (UCLA)

Dr Michael Christmass, Mental Health Commission, WA

Juanita Koeijers, National Mental Health Consumer and Carer Forum

Project description: 

Crystalline methamphetamine (“ice”) is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.

Read more here